PRTC logo

PureTech Health PLC

PRTC

Build a strategy around PRTC

Accountable AI Logo

PureTech Health PLC AI Insights

Informational only. Not investment advice.
As of 2025-12-12

Snapshot

  • Net income of 50.7M TTM driven by 144M unusual items - core operations lost 118M at operating level[Total Unusual Items]
  • Cash of 261M covers 2.1 years of operating burn (118M/yr) with minimal debt (21M) - runway secured[Cash and Equivalents]
  • R&D of 40M TTM exceeds revenue (6.2M) by 6.5x - pre-commercial biotech dependent on pipeline monetization[Research and Development]

Watch Triggers

  • Cash and Equivalents: Falls below 150MBelow 150M signals <18 months runway, forcing dilutive financing or fire-sale asset deals
  • Total Revenue: Exceeds 25M quarterlyWould indicate pipeline commercialization inflection, shifting from asset-sale to recurring revenue model
  • Special Income Charges: Drops to zero for 2+ quartersSignals pipeline monetization pipeline exhausted, accelerating cash burn timeline

Bull Case

Fortress balance sheet (261M cash, 21M debt) funds 2+ years of R&D without dilution while 153M TTM special income proves ability to monetize pipeline assets

Cash and EquivalentsTotal DebtSpecial Income Charges

Trading near cash value (261M) with pipeline optionality - downside protected by liquid assets covering 47% of total assets

Cash and EquivalentsTotal AssetsCurrent Assets

Bear Case

Core operations burning 118M/yr with only 6.2M revenue - requires continuous asset sales or dilution beyond 2027

Operating IncomeTotal RevenueIssuance of Capital Stock

Unusual items (144M) mask true losses - stripping one-time gains reveals unsustainable -94M pretax loss from operations

Total Unusual ItemsPretax IncomeOperating Income

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
45%

Leverage PRTC's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Pipeline monetization events will drive step-change in valuation over 1-3 years

1-3ymed
  • 153M special income TTM signals active asset monetization
  • R&D spend 6.5x revenue indicates late-stage pipeline
  • Net investment sales of 140M shows portfolio harvesting
Special Income Charges TTM: 153MNet Investment Purchase/Sale TTM: 140MCash runway: 2.1 years at current burn

Valuation Context

Caveats

Public Strategies Rankings

See how PureTech Health PLC ranks across different investment strategies.

Leverage PRTC's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.